Antibe Therapeutics Inc. (ATBPF)

0,2156 0,0000 (0,00%) Börsenschluss: 03:46PM EDT

Antibe Therapeutics Inc.

15 Prince Arthur Avenue
Toronto, ON M5R 1B2
Canada
416-922-3460
https://www.antibethera.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 11

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Alain Wilson M.B.A., MBA	Chief Financial Officer	152,7k	N/A	N/A
Mr. Scott Curtis C.F.A., M.Eng	Chief Operating Officer	216,96k	N/A	N/A
Dr. David James Vaughan Ph.D.	Chief Development Officer	297,66k	N/A	1950
Dr. Joseph Stauffer D.O., M.B.A.	Chief Medical Officer	812,59k	N/A	1966
Dr. Ana Stegic	Executive Director of Clinical Operations	188,64k	N/A	N/A
Ms. Christina Cameron B.B.A.	Vice President of Investor Relations	N/A	N/A	N/A
Mr. Philip Stern	Vice President of Communications	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead compound is Otenaproxesul, an NSAID that releases hydrogen sulfide for treating post-operative pain, migraine, acute musculoskeletal pain, dysmenorrhea, gout, and dental pain. In addition, its products comprise ATB-352, which is in preclinical stage for acute pain. The company was incorporated in 2009 and is headquartered in Toronto, Canada.

Corporate Governance

Antibe Therapeutics Inc.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.